<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04878406</url>
  </required_header>
  <id_info>
    <org_study_id>NN9389-4680</org_study_id>
    <secondary_id>U1111-1263-7182</secondary_id>
    <nct_id>NCT04878406</nct_id>
  </id_info>
  <brief_title>A Research Study of How the Medicine NNC0480-0389 Taken With Semaglutide Works in the Body of Healthy Japanese Men</brief_title>
  <official_title>Investigation of Safety, Tolerability and Pharmacokinetics of Subcutaneously Co-administered Single Doses of NNC0480-0389 and Semaglutide in Healthy Japanese Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study looks at how the new medicine called NNC0480-0389 works in the body of Japanese&#xD;
      men when it is given together with semaglutide. Participants will get NNC0480-0389 and&#xD;
      semaglutide or 2 doses of placebo - which treatment participants get is decided by chance.&#xD;
      NNC0480-0389 is a new medicine that has not been previously approved. It means that the&#xD;
      medicine has not yet been approved by the health authorities. Semaglutide is a newly approved&#xD;
      antidiabetic medicine that helps to lower blood sugar levels in patients with type 2&#xD;
      diabetes. NNC0480-0389 is being developed to be given together with semaglutide.NNC0480-0389&#xD;
      targets a different part of the system that regulates sugar levels in the body than&#xD;
      semaglutide. Therefore, it is expected that together NNC0480-0389 and semaglutide will more&#xD;
      effectively lower sugar levels in the blood. Participants will get 2 injections of the study&#xD;
      medicine. It will be injected with a needle into a skin fold on participants' stomach. The&#xD;
      study will last for a maximum of 72 days. Participants will have 10 scheduled visits with the&#xD;
      study doctor. For 1 of the visits participants will stay at the clinic for 6 days (5&#xD;
      nights).The study includes blood sampling.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 18, 2021</start_date>
  <completion_date type="Actual">July 20, 2021</completion_date>
  <primary_completion_date type="Actual">July 20, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Sponsor staff involved in the clinical trial is masked according to company standard procedures.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>From time of dosing (day 1) until completion of the follow-up visit (day 43)</time_frame>
    <description>Count of events</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞,NNC0480-0389,SD: Area under the NNC0480-0389 plasma concentration-time curve from time 0 to infinity upon a single-dose</measure>
    <time_frame>From pre-dose (day 1) to completion of the post-dose follow-up visit (day 43)</time_frame>
    <description>Measured in nmol*h/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,NNC0480-0389,SD: Maximum plasma concentration of NNC0480-0389 upon a single-dose</measure>
    <time_frame>From pre-dose (day 1) to completion of the post-dose follow-up visit (day 43)</time_frame>
    <description>Measured in nmol/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-∞,semaglutide,SD: Area under the semaglutide plasma concentration-time curve from time 0 to infinity upon a single-dose</measure>
    <time_frame>From pre-dose (day 1) to completion of the post-dose follow-up visit (day 43)</time_frame>
    <description>Measured in nmol*h/L</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax,semaglutide,SD: Maximum plasma concentration of semaglutide upon a single-dose</measure>
    <time_frame>From pre-dose (day 1) to completion of the post-dose follow-up visit (day 43)</time_frame>
    <description>Measured in nmol/L</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy Volunteers Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>1.7 mg NNC0480-0389 + 0.5 mg Semaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be co-administered single doses of 1.7 mg NNC0480-0389 and 0.5 mg semaglutide as separate injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (1.7 mg NNC0480-03899) + placebo (0.5 mg Semaglutide)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be co-administered single doses of placebo (NNC0480-0389) and placebo (semaglutide) as separate injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8.6 mg NNC0480-0389 + 0.5 mg Semaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be co-administered single doses of 8.6 mg NNC0480-0389 and 0.5 mg semaglutide as separate injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (8.6 mg NNC0480-0389) + placebo (0.5 mg Semaglutide)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be co-administered single doses of placebo (NNC0480-0389) and placebo (semaglutide) as separate injection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg NNC0480-0389 + 0.5 mg Semaglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be co-administered single doses of 30 mg NNC0480-0389 and 0.5 mg semaglutide as separate injections.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (30 mg NNC0480-0389) + placebo (0.5 mg Semaglutide)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be co-administered single doses of placebo (NNC0480-0389) and placebo (semaglutide) as separate injection.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NNC0480-0389</intervention_name>
    <description>A single dose of subcutaneous NNC0480-0389. The study will last for a maximum of 72 days.</description>
    <arm_group_label>1.7 mg NNC0480-0389 + 0.5 mg Semaglutide</arm_group_label>
    <arm_group_label>30 mg NNC0480-0389 + 0.5 mg Semaglutide</arm_group_label>
    <arm_group_label>8.6 mg NNC0480-0389 + 0.5 mg Semaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (NNC0480-0389)</intervention_name>
    <description>A single dose of subcutaneous placebo (NNC0480-0389) The study will last for a maximum of 72 days.</description>
    <arm_group_label>Placebo (1.7 mg NNC0480-03899) + placebo (0.5 mg Semaglutide)</arm_group_label>
    <arm_group_label>Placebo (30 mg NNC0480-0389) + placebo (0.5 mg Semaglutide)</arm_group_label>
    <arm_group_label>Placebo (8.6 mg NNC0480-0389) + placebo (0.5 mg Semaglutide)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Semaglutide</intervention_name>
    <description>A single dose of subcutaneous Semaglutide 0.5 mg The study will last for a maximum of 72 days.</description>
    <arm_group_label>1.7 mg NNC0480-0389 + 0.5 mg Semaglutide</arm_group_label>
    <arm_group_label>30 mg NNC0480-0389 + 0.5 mg Semaglutide</arm_group_label>
    <arm_group_label>8.6 mg NNC0480-0389 + 0.5 mg Semaglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (Semaglutide)</intervention_name>
    <description>A single dose of subcutaneous placebo (semaglutide) The study will last for a maximum of 72 days.</description>
    <arm_group_label>Placebo (1.7 mg NNC0480-03899) + placebo (0.5 mg Semaglutide)</arm_group_label>
    <arm_group_label>Placebo (30 mg NNC0480-0389) + placebo (0.5 mg Semaglutide)</arm_group_label>
    <arm_group_label>Placebo (8.6 mg NNC0480-0389) + placebo (0.5 mg Semaglutide)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male aged 20-55 years (both inclusive) at the time of signing the informed consent.&#xD;
&#xD;
          -  Both parents of Japanese descent.&#xD;
&#xD;
          -  Body mass index between 20.0 kg/m^2 and 24.9 kg/m^2 (both inclusive).&#xD;
&#xD;
          -  Considered to be generally healthy based on the medical history, physical examination,&#xD;
             and the results of vital signs, electrocardiogram and clinical laboratory tests&#xD;
             performed during the screening visit, as judged by the investigator.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any disorder which in the investigator's opinion might jeopardise subject's safety or&#xD;
             compliance with the protocol.&#xD;
&#xD;
          -  Glycated haemoglobin (HbA1c) greater than or equal to 6.5% (48 mmol/mol) at screening.&#xD;
&#xD;
          -  Use of prescription medicinal products or non-prescription drugs, except routine&#xD;
             vitamins, occasional use of acetaminophen, ibuprofen and acetylsalicylic acid, or&#xD;
             topical medication not reaching systemic circulation within 14 days prior to the day&#xD;
             of screening.&#xD;
&#xD;
          -  Presence or history of any clinically relevant respiratory, metabolic, renal, hepatic,&#xD;
             cardiovascular, gastrointestinal, or endocrinological conditions.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Transparency (Dept.1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Fukuoka</city>
        <zip>812-0025</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 5, 2021</study_first_submitted>
  <study_first_submitted_qc>May 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>According to the Novo Nordisk disclosure commitment on novonordisk-trials.com</ipd_description>
    <ipd_url>http://novonordisk-trials.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

